Novo Nordisk Pharmatech A/S

Delivering excellence at every step

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then.

On 1 September 2015 the company’s name was changed to Novo Nordisk Pharmatech A/S.  It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.

These products are manufactured to cGMP standards, and in both product areas the company has distinguished itself for:

  • Global regulatory compliance
  • Consistent high quality
  • Extensive regulatory documentation
  • Continuous availability
  • Secure global supply chain
  • High levels of service and support

Best-Quality Insulin

Novo Nordisk Pharmatech has become the leading supplier of insulin for cell culture processes by providing excellence at every step of the supply chain – beginning with the quality of its insulin, which is sourced directly from Novo Nordisk, the world’s largest producer. Its recombinant insulin is a key component in serum free growth media for mammalian cells. It is used for the manufacturing of monoclonal antibodies, virus vaccines, gene therapy products and many other biological drug products approved by regulatory bodies worldwide, including FDA and EMA.

High-Purity Quaternary Ammonium Compounds (Quats)

An innovative synthesis process makes Novo Nordisk Pharmatech a leading supplier of crystalline Quats for a wide range of applications. High levels of purity make them particularly suited for pharmaceutical applications, such as vaccine production. They act either as preservatives or active ingredients in many ophthalmic, nasal, oral and topical drugs and in a variety of solutions, ointments and creams. Their purity and characteristics are also ideal for a range of personal care products.

Triple bottom line

Novo Nordisk Pharmatech manages its business in accordance with the Triple Bottom Line (TBL) business principle, conducting activities in a financially, environmentally and socially responsible way,

Categories

View all Categories

You are about to contact Novo Nordisk Pharmatech A/S. Please fill in the form below and your enquiry will be sent directly to the supplier's email address.

Fields marked with are required

Enquiry sent

Your enquiry has been sent successfully to Novo Nordisk Pharmatech A/S. You will be contacted by one of their representatives shortly.

Would you like to receive enquiries like the one you have just sent?

Add your company for free below!

Thank you for using Copybook. Click here to send another enquiry.

Error

Oops... An error occured during your enquiry submission.

Please try again later or contact the system administrator at admin@copybook.com.

Click here to re-send the enquiry.

Contact details

Phone

+45 5667 1000

Fax

+45 5667 1001

Novo Nordisk Pharmatech A/S
Københavnsvej 216
4600, Koege
Denmark

page up